ONC: Flat Base detected on 24 Sep 2026

ONC is forming a flat base pattern with solid technical construction. At $365.00, the stock sits 5.25% below its 52-week high of $385.22 and well above key support at $309.94—providing a 1.78:1 reward-to-risk ratio. The structure score (9.0) and volume score (9.0) are balanced, while breakout strength measures 11.0, indicating average breakout power. Volume surged 71% above average (1.71x ratio) on recent sessions. RSI at 57.83 shows neutral momentum, and positive MACD histogram (0.0553) suggests early upside initiation. The measured move target is $382.29, requiring a 4.7% move through current resistance at $380.00.

BeiGene reported strong Q2 2026 financial results with $1.7 billion in total revenues and $2.05 in GAAP earnings per ADS, representing 30% and 144% growth year-over-year, respectively. The company raised its 2026 guidance for revenue and GAAP operating income by $300 million and $250 million, respectively, driven by the performance of Brukinsa, which achieved over $1.2 billion in global revenues, marking a 31% year-over-year growth. 27 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The average 12-month price target for BeOne Medicines DRC is 432.90 USD. The biotech's strong earnings momentum and product delivery are fueling confidence in the stock, supporting the bullish pattern setup.

A successful breakout above $380.00 resistance should drive price toward the conservative target of $382.29, with potential extension higher given analyst upside targets near $432.90. Volume confirmation is critical—the setup requires sustained volume above the 1.7x relative average seen recently to validate breakout authenticity. The win probability score of 55.56% reflects moderate confidence in pattern success. Invalidation occurs below support at $309.94, representing a 15.2% downside risk from current levels. The low beta (0.31) suggests ONC will move on company-specific fundamentals rather than broad market swings.

Drug pipeline approvals may be less successful than previously forecast. The 3-month gain of 31.71% indicates stock has already rallied substantially, potentially limiting additional upside before consolidation. Flat base patterns have moderate reliability (55.56% win probability) compared to other structures. However, risk appears contained: no current short interest is reported, the Health Care sector regime is bullish (0.62 score), and broader market regime is strongly bullish (0.95 score). The company raised full-year guidance post-Q2 earnings, reducing near-term earnings risk. Monitor for clinical trial setbacks or regulatory delays in the pipeline, which could trigger breakdown below support.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.